IDL Biotech signs distributor agreement in Ghana
IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.
The Annual General meeting was held on the 28th of May 2019.
Read the information here (in swedish).
IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.
IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.